Cnidium coumarin is used to prepare the purposes of antifungal drug synergist product

An antifungal drug, a technology of coumarin, applied in the field of medicine, can solve the problem of no public report on the synergistic antifungal effect, achieve good application prospect, wide application prospect, and improve the effect of antifungal effect

Inactive Publication Date: 2018-01-05
SECOND MILITARY MEDICAL UNIV OF THE PEOPLES LIBERATION ARMY
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, when used in combination with other drugs, there is no public report on the synergistic antifungal effect

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Cnidium coumarin is used to prepare the purposes of antifungal drug synergist product
  • Cnidium coumarin is used to prepare the purposes of antifungal drug synergist product
  • Cnidium coumarin is used to prepare the purposes of antifungal drug synergist product

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0011] Example 1: The effect of the combination of methoxycarvacrol and fluconazole on different clinical fungal strains

[0012] Materials and methods

[0013] 1. Test drug:

[0014] Methoxyparscreol: provided by Xi'an Luquan Biotechnology Co., Ltd., prepared with DMSO.

[0015] Fluconazole injection: Pfizer Pharmaceutical Co., Ltd., batch number 9149102.

[0016] All reagents were stored at -20°C. Before the experiment, the drug was taken out and placed in a 35°C incubator to melt, mixed well, and pharmacodynamic tests were carried out respectively.

[0017] 2. Strains:

[0018] Clinical strains: Drug-resistant Candida albicans (100, J35, 32, 557, 842, 901, 103, J28, J5, 904, 953), all provided by the Fungi Department of Shanghai Changhai Hospital, collected from clinical samples of different departments of Changhai Hospital , and were identified morphologically and biochemically.

[0019] All the experimental strains were activated on sandcastle dextrose agar (SDA) me...

Embodiment 2

[0044] Example 2: Diffusion experiment on agar plate in combination with methoxyparvacrol and fluconazole

[0045] Materials and methods

[0046] Strains: Clinical drug-resistant Candida albicans No. 0304103, provided by the Fungi Department of Changhai Hospital, and identified by morphology and biochemistry.

[0047] Drug: fluconazole injection (Diflucan, Diflucan) is produced by Pfizer Biopharmaceutical Co., Ltd. of the United States. Methoxyparserol (osthol) was provided by Xi'an Luquan Biotechnology Co., Ltd. and prepared in DMSO.

[0048] Reagents: YEPD culture fluid, YEPD solid medium, DMSO, 0.9% physiological saline, sterile white paper (diameter 6mm).

[0049]YEPD solid medium: 10g of yeast extract, 20g of peptone, 20g of glucose, 20g of agar, add 900ml of triple distilled water to dissolve, adjust the volume to 1000ml with triple distilled water, autoclave (121°C, 15min), spread the liquid while hot Store in a sterile petri dish (diameter 90mm) at 4°C for later use...

Embodiment 3

[0054] Example 3: The protective effect of combined use of methoxyparvacrol and fluconazole on systemic fungal infection in mice

[0055] Test design:

[0056] 50 ICR mice were injected into the tail vein with 5×10 6 CFU / ml logarithmic growth phase Candida albicans suspension 0.2ml, replicate systemic mouse deep fungal infection model, and randomly divide into the following 5 groups: model group, fluconazole 0.5mg / ml group, fluconazole Azole 0.5mg / ml+methoxyparscreol 75mg / ml group, fluconazole 0.5mg / ml+methoxyparscreol 150mg / ml group, fluconazole 0.5mg / ml+methoxyparscreol 300mg / ml Group.

[0057] Two hours after modeling, the drug was administered by intragastric administration, with a volume of 0.2ml / 10g, once a day for four consecutive days. The mice were observed for death within 30 days after the start of administration.

[0058] statistical methods:

[0059] Kaplan-Meier survival analysis, statistical software SPSS17.0.

[0060] Experimental results

[0061] The ef...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
melting pointaaaaaaaaaa
boiling pointaaaaaaaaaa
diameteraaaaaaaaaa
Login to view more

Abstract

The invention relates to the technical field of medicine, and relates to the use of osthole coumarin for preparing antifungal drug synergist products. Through in vitro and in vivo experiments, the combination of cnidium coumarin and fluconazole can significantly improve the therapeutic effect on deep fungal infections, and can restore the effect of antifungal drugs on drug-resistant fungi. Therefore, it can be used as a synergist for antifungal drugs.

Description

Technical field: [0001] The invention relates to the technical field of medicine, and relates to the application of cnidium coumarin in preparing antifungal drug synergist products. Background technique [0002] The traditional Chinese medicine Cnidium is the fruit of Cnidium monnieric (L.) Cuss, an annual herb of Umbelliferae. Modern chemical research shows that the main components are coumarins and terpenoids. At present, the pharmacological action and application research of the active ingredients in Cnidium Fructus mainly focuses on coumarins, which are called Total Cnidium Coumarin (TCCM). There are 6 monomers that have been separated from TCCM, including methoxy Parsvelol, bergamot lactone, isoxaxifragenin, xanthoxylin, xanthoxylin, parsley element B. It has a broad-spectrum antibacterial effect, and has a strong inhibitory effect on beard, toe, and perianal ringworm, and has an inhibitory effect on vaginal trichomonas. However, there is no public report on the syner...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/37A61K36/234A61P31/10
Inventor 姜远英李林鹏曹永兵林辉李洪娇
Owner SECOND MILITARY MEDICAL UNIV OF THE PEOPLES LIBERATION ARMY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap